Status:
COMPLETED
The Role of Dopaminergic and Noradrenergic Neurotransmission in Value- and Salience-based Decision-Making
Lead Sponsor:
University of Zurich
Conditions:
Healthy
Eligibility:
All Genders
18-35 years
Phase:
NA
Brief Summary
Approach versus avoidance decisions are at the centre of adaptive behaviour and survival. These decisions are thought to be guided by the value of the choice options, which are a function of the magni...
Eligibility Criteria
Inclusion
- Physically and psychiatrically healthy men and women aged ≥ 18- ≤ 35 years
- Ability and willingness to participate in the study
- Signed informed consent
Exclusion
- Serious past brain disease or injury (data quality)
- Frequent headaches (of any sort, \> 1/week) or migraine (irrespective of frequency)
- History of epileptic seizures
- Any neurological disorder
- Surgery to head or heart (safety, potential metal pieces)
- Pacemaker, hearing aid or neurostimulator (safety, metal pieces)
- Known cardiac or cardiovascular disease or anomaly
- Family history of sudden death due to cardiac arrhythmia
- High or low blood pressure, history of heart attack, infrequent heartbeat
- Respiratory problems (including difficulty with breathing through the nose)
- Glaucoma (present or in history)
- Insufficiency of kidney or liver, acute liver disease
- Any psychiatric disorder (especially depression, mania, schizophrenia, addiction and suicidality)
- Severe vocal or motor tics (methylphenidate, data quality)
- Severe psychosomatic disorder (somatic complaints without clear medical cause, has a mental component)
- Pregnancy, nursing, or currently planned pregnancy
- Current allergy in general or allergy to methylphenidate or reboxetine
- Severe intolerance to lactose including strong diarrhea after only a few mg (weak lactose intolerance is no exclusion criterion as medication only contains slightest dosage (around 4mg) of lactose)
- Currently taking any medication that might interfere with Methylphenidate and Reboxetine, especially MAO-Inhibitors (e.g. Aurorix (Moclobemid) und Azilect (Rasagilin), antipsychotics, antibiotics, and medication for heart diseases
- Currently taking any further medication (besides birth control) or natural products (infrequent intake of natural products and/or food supplements need to be mentioned to the examiner)
- Drug abuse (current or past abuse; in case of single use please inform the examiner)
- Serious acute or chronic disease that could interfere with participation in the experiments
- Inability to understand the instructions or insufficient comprehension of German language
- Participants having their weight outside of the range of ≥ 60 kg - ≤ 80 kg
- Clinically relevant score in STAI T (anxiety), measured during prescreening on a separate day
- Long QT syndrome or other arrhythmias, measured during prescreening on a separate day
Key Trial Info
Start Date :
July 3 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 13 2020
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04371146
Start Date
July 3 2019
End Date
February 13 2020
Last Update
May 1 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Zurich
Zurich, Switzerland, 8006